Recombinant Mycobacterium bovis bacillus calmette-guérin vectors prime for strong cellular responses to simian immunodeficiency virus gag in rhesus macaques

Clinical and Vaccine Immunology

Volumn 21, Issue 10, 2014, Pages 1385-1395

  Sixsmith, Jaimie D ^a   Panas, Michael W ^a,d   Lee, Sunhee ^b   Gillard, Geoffrey O ^a,e   White, Keri Ann ^a   Lifton, Michelle A ^a   Balachandran, Harikrishnan ^a   Mach, Linh ^a   Miller, John P ^a,f   Lavine, Christy ^a   De Marco, C Todd ^b   Tomaras, Georgia D ^b   Gee, Connie ^a   Porcelli, Steven A ^c   Larsen, Michelle H ^c   Frothingham, Richard ^b   Schmitz, Joern E ^a   Jacobs, William R ^c   Haynes, Barton F ^b   Letvin, Norman L ^a   Korioth Schmitz, Birgit ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e BIOGEN   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAG PROTEIN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RETROVIRUS VECTOR; DRUG CARRIER; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE RELEASE; GENE CASSETTE; GENE DELETION; IMMUNOGENICITY; IMMUNOSTIMULATION; IN VITRO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MYCOBACTERIUM BOVIS BCG; NONHUMAN; PROTEIN EXPRESSION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY; MYCOBACTERIUM BOVIS; TREATMENT OUTCOME;

ANIMALS; DRUG CARRIERS; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNITY, CELLULAR; MACACA MULATTA; MYCOBACTERIUM BOVIS; RECOMBINANT PROTEINS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84907519311     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00324-14     Document Type: Article

References (41)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Mi-chael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220. http://dx.doi.org/10.1056/NEJMoa0908492.
2. World Health Organization, Expert Committee on Biological Standardization. 2011. Recommendations to assure the quality, safety and efficacy of BCG vaccines. World Health Organization, Geneva, Switzerland.
3. Centers for Disease Control. 1996. The role ofBCGvaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the AdvisoryCommittee on Immunization Practices.MMWRRecomm. Rep. 45: 1-18
4. Merle CS, Cunha SS, Rodrigues LC. 2010. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines 9:209-222. http://dx.doi.org/10.1586/erv.09.161.
5. Brewer TF. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31(Suppl 3): S64 -S67. http://dx.doi.org/10.1086/314072.
6. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
7. Chapman R, Chege G, Shephard E, Stutz H, Williamson AL. 2010. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr. HIV Res. 8:282-298. http://dx.doi.org/10.2174/157016210791208686.
8. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR, Jr, Bloom BR. 1991. New use of BCG for recombinant vaccines. Nature 351:456-460. http://dx.doi.org/10.1038/351456a0.
9. Langermann S, Palaszynski SR, Burlein JE, Koenig S, Hanson MS, Briles DE, Stover CK. 1994. Protective humoral response against pneumococcal infection in mice elicited by recombinant Bacille Calmette-Guerin vaccines expressing pneumococcal surface protein A. J. Exp. Med. 180:2277-2286. http://dx.doi.org/10.1084/jem.180.6.2277.
10. Joseph J, Saubi N, Pezzat E, Gatell JM. 2006. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guerin: failures and challenges. Expert Rev. Vaccines 5:827-838. http://dx.doi.org/10.1586/14760584.5.6.827.
11. Cayabyab MJ, Korioth-Schmitz B, Sun Y, Carville A, Balachandran H, Miura A, Carlson KR, Buzby AP, Haynes BF, Jacobs WR, Letvin NL. 2009. Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J. Virol. 83: 5505-5513. http://dx.doi.org/10.1128/JVI.02544-08.
12. Glickman MS, Cahill SM, Jacobs WR, Jr. 2001. The Mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid trans-cyclopropane synthetase. J. Biol. Chem. 276:2228-2233. http://dx.doi.org/10.1074/jbc.C000652200.
13. Bardarov S, Bardarov S, Jr, Pavelka MS, Jr, Sambandamurthy V, Larsen M, Tufariello J, Chan J, Hatfull G, Jacobs WR, Jr. 2002. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in Mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology 148:3007-3017.
14. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
15. Knapp LA, Lehmann E, Piekarczyk MS, Urvater JA, Watkins DI. 1997. A high frequency of Mamu-A∗01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50:657-661. http://dx.doi.org/10.1111/j.1399-0039.1997.tb02927.x.
16. Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR. 2014. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505:502-508. http://dx.doi.org/10.1038/nature12893.
17. Kuroda MJ, Schmitz JE, Barouch DH, Craiu A, Allen TM, Sette A, Watkins DI, Forman MA, Letvin NL. 1998. Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1373-1381. http://dx.doi.org/10.1084/jem.187.9.1373.
18. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. 2002. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 260:157-172. http://dx.doi.org/10.1016/S0022-1759 (01)00535-X.
19. Hagiwara E, Abbasi F, Mor G, Ishigatsubo Y, Klinman DM. 1995. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-alpha in human peripheral blood. Cytokine 7:815-822. http://dx.doi.org/10.1006/cyto.1995.0098.
20. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulinM( IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449-12463. http://dx.doi.org/10.1128/JVI.01708-08.
21. Montefiori DC. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol. Chapter 12:Unit 12 11. http://dx.doi.org/10.1002/0471142735.im1211s64.
22. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA. 1999. Control of viremia in simian immunodeficiency virus infection by CD8-lymphocytes. Science 283:857-860. http://dx.doi.org/10.1126/science.283.5403.857.
23. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91. http://dx.doi.org/10.1038/nature07469.
24. Weerdenburg EM, Peters PJ, van der Wel NN. 2010. How do mycobacteria activate CD8-T cells? Trends Microbiol. 18:1-10. http://dx.doi.org/10.1016/j.tim.2009.10.004.
25. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, Sandhoff K, Brinkmann V, Kaufmann SH, Schaible UE. 2006. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24: 105-117. http://dx.doi.org/10.1016/j.immuni.2005.12.001.
26. Rao V, Gao F, Chen B, Jacobs WR, Jr, Glickman MS. 2006. Transcyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis-induced inflammation and virulence. J. Clin. Invest. 116:1660-1667. http://dx.doi.org/10.1172/JCI27335.
27. Barkan D, Hedhli D, Yan HG, Huygen K, Glickman MS. 2012. Mycobacterium tuberculosis lacking all mycolic acid cyclopropanation is viable but highly attenuated and hyperinflammatory in mice. Infect. Immun. 80:1958-1968. http://dx.doi.org/10.1128/IAI.00021-12.
28. Lopez M, Sly LM, Luu Y, Young D, Cooper H, Reiner NE. 2003. The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2. J. Immunol. 170:2409-2416. http://dx.doi.org/10.4049/jimmunol.170.5.2409.
29. Sanchez A, Espinosa P, Garcia T, Mancilla R. 2012. The 19 kDa Mycobacterium tuberculosis lipoprotein (LpqH) induces macrophage apoptosis through extrinsic and intrinsic pathways: a role for the mitochondrial apoptosis-inducing factor. Clin. Dev. Immunol. 2012:950503. http://dx.doi.org/10.1155/2012/950503.
30. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R, O'Gaora P, Herrmann JL, Prevost MC, Perret E, Thole JE, Young D. 2001. Lipoprotein access to MHC class I presentation during infection of murine macrophages with live mycobacteria. J. Immunol. 166:447-457. http://dx.doi.org/10.4049/jimmunol.166.1.447.
31. Dennehy M, Williamson AL. 2005. Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23:1209-1224. http://dx.doi.org/10.1016/j.vaccine.2004.08.039.
32. Al-Zarouni M, Dale JW. 2002. Expression of foreign genes in Mycobacterium bovis BCG strains using different promoters reveals instability of the hsp60 promoter for expression of foreign genes in Mycobacterium bovisBCGstrains. Tuberculosis (Edinb.) 82:283-291. http://dx.doi.org/10.1054/tube.2002.0374.
33. Yasutomi Y, Koenig S, Haun SS, Stover CK, Jackson RK, Conard P, Conley AJ, Emini EA, Fuerst TR, Letvin NL. 1993. Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J. Immunol. 150:3101-3107.
34. Stevceva L, Alvarez X, Lackner AA, Tryniszewska E, Kelsall B, Nacsa J, Tartaglia J, Strober W, Franchini G. 2002. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8() T-cell responses in mucosal tissues of macaques. J. Virol. 76: 11659-11676. http://dx.doi.org/10.1128/JVI.76.22.11659-11676.2002.
35. Hel Z, Nacsa J, Tryniszewska E, Tsai WP, Parks RW, Montefiori DC, Felber BK, Tartaglia J, Pavlakis GN, Franchini G. 2002. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre-and postchallenge CD4-and CD8-T cell responses. J. Immunol. 169:4778-4787. http://dx.doi.org/10.4049/jimmunol.169.9.4778.
36. Sircar P, Furr KL, Letvin NL. 2013. Systemic vaccination induces clonally diverse SIV-specific CD8-T-cell populations in systemic and mucosal compartments. Mucosal Immunol. 6:93-103. http://dx.doi.org/10.1038/mi.2012.52.
37. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M, Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15: 293-299. http://dx.doi.org/10.1038/nm.1935.
38. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr, Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-527. http://dx.doi.org/10.1038/nature10003.
39. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, Davies ME, McDermott AB, O'Connor DH, Fridman A, Bagchi A, Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79: 15547-15555. http://dx.doi.org/10.1128/JVI.79.24.15547-15555.2005.
40. Ami Y, Izumi Y, Matsuo K, Someya K, Kanekiyo M, Horibata S, Yoshino N, Sakai K, Shinohara K, Matsumoto S, Yamada T, Yamazaki S, Yamamoto N, Honda M. 2005. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J. Virol. 79:12871-12879. http://dx.doi.org/10.1128/JVI.79.20.12871-12879.2005.
41. Plotkin SA. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-409. http://dx.doi.org/10.1086/589862.